Winnie Community Hospital, LLC

Winnie Community Hospital, LLC was paid $3.09M by Medicaid between May 2020 and Dec 2024, across 63 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 50% of everything it billed.

Compared with peers

Next to other Critical Access Hospital providers in Texas

Rank by total paid#3 of 47

Median peer was paid$170K

This provider vs. median18×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	1,965	$191K
2021	13,229	$978K
2022	17,295	$1.10M
2023	14,495	$536K
2024incomplete	10,280	$292K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	50%	5,473	5,211	$1.54M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	11%	7,273	6,931	$339K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	9.8%	3,414	3,237	$304K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	9.3%	953	905	$287K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	3.3%	1,344	1,269	$103K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.2%	3,390	3,218	$67K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.5%	1,758	1,671	$46K
87486		1.2%	1,086	1,034	$36K
87581		1.2%	1,085	1,033	$36K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	1.1%	198	195	$34K
99282	Emergency department visit for the evaluation and management, low to moderate severity	1.0%	206	203	$32K
87640		1.0%	1,088	1,027	$32K

51 more codes

99000		<1%	1,819	$30K
87541		<1%	892	$30K
80053	Comprehensive metabolic panel	<1%	2,619	$25K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	864	$16K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	2,193	$12K
99283	Emergency room visit (moderate)	<1%	46	$12K
84443	Thyroid stimulating hormone (TSH)	<1%	1,104	$11K
99001		<1%	659	$10K
80061	Lipid panel	<1%	1,183	$9K
80074		<1%	198	$7K
84481		<1%	503	$6K
G0659	Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes	<1%	1,756	$5K
87529		<1%	179	$5K
83036	Hemoglobin; glycosylated (A1C)	<1%	772	$5K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	226	$4K
84439		<1%	728	$4K
0071A		<1%	51	$4K
82607		<1%	417	$3K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	121	$3K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	93	$3K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	188	$3K
G0410	Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes	<1%	8,898	$3K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	188	$3K
87631		<1%	21	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	184	$2K
87481		<1%	57	$2K
82746		<1%	167	$2K
90832	Psychotherapy session, about 30 minutes	<1%	584	$1K
87653		<1%	27	$1K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	60	$1K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	31	$953.87
87511		<1%	153	$906.21
0072A		<1%	17	$821.63
0002A		<1%	25	$810.12
87500		<1%	69	$734.02
87641		<1%	69	$589.81
87086	Culture, bacterial; quantitative colony count, urine	<1%	111	$533.23
87430		<1%	30	$483.24
83655		<1%	37	$421.31
82728		<1%	39	$400.75
84480		<1%	31	$378.40
0001A		<1%	36	$207.00
84436		<1%	31	$183.88
90791	Psychiatric diagnostic evaluation	<1%	28	$173.72
83540		<1%	28	$157.56
81001		<1%	73	$135.12
36415	Collection of venous blood by venipuncture	<1%	1,944	$43.92
82550		<1%	14	$5.20
81003		<1%	12	$2.16
G0177	Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more)	0%	369	$0.00
96156		0%	52	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialDANISHMUND, MOHAMMED (CFO)

Same official

Other billing entities under DANISHMUND, MOHAMMED

Full network →

Provider	Location	Paid
Winnie Community Hospital, LLC	Winnie, TX	$1.07M
Winnie Community Hospital, L.L.C.	Winnie, TX	$50K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.